



# **The GM Care Record**

## March 2021: Stakeholder Brief

This monthly briefing provides an update on the progress made in enabling data sharing across health and care in Greater Manchester via the **GM Care Record**.

NOTE: You are welcome to circulate this brief within your own organisation, but please don't share publicly.

## Latest developments



#### **Direct Care**

Usage of the GM Care Record (GMCR) continues to grow with **87,108** patients accessed through the record for direct care by **9,783** frontline users in February 2021. The number of frontline users has more than doubled since March 2020.

100% of acute, mental health, GP and the Christie data feeds are now complete into the GMCR. Over a third of council social care feeds are now live with dates for the remaining feeds being explored.

#### **Future Use Cases**

Several use cases are in development that will add significantly to the functionality of the GM Care Record. These include (amongst others):

- Deployment of the GMCR into community pharmacy, care homes and hospices
- COVID-19 Oximetry at Home and Virtual Wards
- Remote monitoring of blood pressure and glucose in high-risk pregnancies
- Digital heart failure and dementia/frailty care plans
- PACS viewer integration

We are working through the details of these with the localities to establish a roadmap for their development and deployment in GM.


We will shortly publish more details about these use cases in a future edition of this stakeholder brief.

## Research and Secondary Uses

In response to the COVID-19 pandemic, deidentified patient data in the GM Care Record is being used to understand more about pandemic in GM, why the cityregion has been disproportionately affected along with certain communities and patient groups.

The legal basis for use of GM Care Record patient data is defined in the national Control of Patient Information (COPI) notice (now extended to 30<sup>th</sup> September 2021), which gives NHS organisations a legal requirement to share data for the purposes of the COVID-19 response.

In order to control who has access to this data and to ensure its safe, legal and transparent use, the following governance arrangements have been established:



Details of the COVID-19 related research that is progressing in Greater Manchester can be found on the next page, with more information on each of the governance groups found at the link below.

GM Care Record for Secondary Uses and Research

# Approved COVID-19 related research using deidentified patient data from the GM Care Record



All 10 GM localities have approved that the COVID-19 Expert Review Group (ERG) can consider and authorise requests for COVID-19 related secondary uses and research using GMCR data. Three studies have so far been approved by the ERG and a further 18 requests are being assessed. The studies that have been approved are:

The equitability of the UK government's COVID-19 vaccination strategy

Principal Investigator:
Dr. Ruth Watkinson,
The University of Manchester

**Summary:** The government plan for the rollout of the COVID-19 vaccines aims to protect the most vulnerable first, giving priority access to people with the highest risk of hospitalisation or mortality from COVID-19.

The aim is to use GM Care Record data from across Greater Manchester to test whether the government vaccination plan meets the goal of giving equal priority to people with equal vulnerability to COVID-19. Healthcare utilisation across GM during the COVID-19 Pandemic

Principal Investigator:
Dr. Stuart Grant,
The University of Manchester

Summary: The GM Care Record will be used to study how the healthcare system in Greater Manchester has been used throughout the pandemic. For example, how busy GP surgeries are, how many routine operations are conducted, and how full the hospitals are.

These analyses will give important insights into bottlenecks in the system that will help with planning for subsequent waves and future pandemics.

COVID-19 incidence, hospital admission and death in cancer patients in GM.

Principal Investigator:
Professor Corinne Faivre-Finn,
University of Manchester

Summary: The GM Care Record will be used to determine the risks and factors associated with COVID-19 diagnosis, hospital admission and death in cancer patients. Hospitalisation and death data will be linked for the first time to primary electronic health records in GM.

This work will provide an overall picture of COVID-19 risk in all GM patients with cancer and help inform individual management decisions for cancer patients.

# Feedback from the frontline - Fiona Lynch, Infectious Disease Pharmacist, MFT

I find using GMCR so, so useful and couldn't do my job as effectively without it. It is useful for getting bloods results that have been done by the GP, checking what other medication patients are on, and if they have been seen in another hospital.

I picked up that a patient had suffered an adverse reaction to a drug we prescribe that we had no idea about as it was reviewed at Salford. I noticed the letter when I was checking a patient's bloods on the GMCR. This led to the patient's clinic appointment being brought forward to review his therapy - so had a massive impact on patient care.

Due to the pandemic, we are relying on GPs to do a lot more of our bloods monitoring for patients and the GMCR is such a useful resource to be able to check these bloods without having to spend ages trying to get through to a GP surgery.

# WEBINAR: The GM Care Record – Supporting You and Your Patients Through COVID-19 and Beyond







r Paula Bennett









Catch-up on the latest GM Care Record webinar we ran on 25<sup>th</sup> February 2021 for frontline health and care workers. We demonstrated what is coming to the GM Care Record later in 2021 including:

- o COVID-19 Oximetry at Home
- Remote monitoring of blood pressure and glucose for highrisk pregnancies
- Accessing cancer records from the Christie

**WATCH NOW!**